Endomyocardial Biopsy Market Size & Growth Forecast 2027–2036, By Segments (Product, End Use, Tip), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Endomyocardial Biopsy Market size was estimated at USD 416 million in 2026 and is projected to grow at a 6.56% CAGR from 2027 to 2036, exceeding USD 785.3 million by 2036. The industry revenue for 2027 is calculated at USD 438.96 million.
Get more details on this report
Request Free Sample ReportEndomyocardial Biopsy Market Intelligence Snapshot
Regional Market Dynamics
- North America captured a 45.58% share in 2026 due to advanced cardiac care infrastructure, specialized cardiology centers, and integrated clinical pathways supporting routine biopsy procedures.
- Asia Pacific is expected to grow at a 7.8% CAGR as cardiac care capabilities improve, tertiary hospitals expand interventional cardiology services, and advanced diagnostic procedures gain wider adoption.
Segment Momentum
- Forceps captured 69.02% of the market in 2026 because they are the essential instrument for reliable tissue retrieval, making them indispensable to established cardiac biopsy procedures.
- Ambulatory surgical centers are expanding fastest as healthcare shifts suitable procedures toward efficient outpatient settings with streamlined workflows and improved scheduling flexibility.
Market Expansion Drivers
- Rising cardiovascular disease burden from sedentary lifestyle and metabolic risk factors increasing diagnostic demand.
- Increasing heart transplant procedures expanding routine post-transplant rejection monitoring via biopsy.
- Advancements in minimally invasive biopsy catheter systems improving procedural safety and adoption rates.
Leading Market Participants
- Leading players in the endomyocardial biopsy market include Terumo Corporation (Japan), Cordis Corporation (United States), Argon Medical Devices, Inc. (United States), Mermaid Medical A/S (Denmark), Scholten Surgical Instruments, Inc. (United States), Changzhou Lookmed Medical Instrument Co., Ltd. (China), Fehling Instruments GmbH & Co. KG (Germany), Biotronik SE & Co. KG (Germany), Boston Scientific Corporation (United States), Medtronic plc (Ireland).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 416 million
- 2027 Estimated Market Size: USD 438.96 million.
- Projected Market Size: USD 785.3 million by 2036
- Growth Forecast: 6.56% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Forceps (Product) | Hospitals (End Use) | Straight (Tip)
- Emerging Opportunity Segment: Accessories (Product) | Ambulatory Surgical Centers (End Use) | Precurved (Tip)
Market Growth Drivers and Industry Trends
Rising cardiovascular disease burden from sedentary lifestyle and metabolic risk factors increasing diagnostic demand
The growing burden of cardiovascular conditions will drive the endomyocardial biopsy market growth as sedentary lifestyles and metabolic risk factors increase the need for detailed cardiac assessment. Biopsy procedures provide tissue-level information that can support evaluation of myocardial abnormalities, particularly when conventional diagnostic approaches require additional clinical confirmation.
Increasing heart transplant procedures expanding routine post-transplant rejection monitoring via biopsy
As heart transplantation becomes an important treatment pathway, the endomyocardial biopsy market growth is supported by the need for routine surveillance of transplanted cardiac tissue. Biopsy remains an established approach for assessing potential rejection following transplantation, creating recurring procedural demand during post-transplant monitoring and follow-up care.
Advancements in minimally invasive biopsy catheter systems improving procedural safety and adoption rates
Advances in minimally invasive catheter technologies will propel the endomyocardial biopsy market growth by addressing procedural concerns and improving the practicality of tissue sampling. More refined catheter systems can support safer access and greater procedural control, making biopsy-based monitoring more suitable for repeated cardiac evaluation.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of cardiac disorders | 2.00% | Short term (≤ 2 yrs) | North America, Europe (spillover: Asia Pacific) | High | Fast |
| Technological advancement in minimally invasive biopsy | 1.50% | Medium term (2–5 yrs) | Europe, Asia Pacific (spillover: North America) | Medium | Moderate |
| Expansion of diagnostic labs in emerging economies | 1.00% | Long term (5+ yrs) | North America, Europe (spillover: Asia Pacific) | Medium | Slow |
| Rising cardiovascular disease burden from sedentary lifestyle and metabolic risk factors increasing diagnostic demand | 2.60% | Moderate | North America, Europe | High | Near Term |
| Increasing heart transplant procedures expanding routine post-transplant rejection monitoring via biopsy | 2.80% | High | North America, Europe | High | Mid Term |
| Advancements in minimally invasive biopsy catheter systems improving procedural safety and adoption rates | 2.20% | Moderate | North America, Asia Pacific | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America led the endomyocardial biopsy market with a 45.58% share in 2026, supported by advanced cardiovascular care infrastructure, strong availability of specialized diagnostic facilities, and established expertise in transplant medicine. The region's sophisticated healthcare systems facilitate the use of invasive cardiac diagnostic procedures for evaluating transplant rejection, cardiomyopathies, and other myocardial conditions. Continued investment in cardiac research, access to specialized pathology services, and integration of advanced imaging and laboratory diagnostics further strengthen clinical capabilities. The presence of experienced cardiovascular specialists and growing emphasis on precise disease monitoring also supports sustained utilization of endomyocardial biopsy procedures.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing regional market, driven by improving cardiovascular healthcare infrastructure, expanding access to specialized medical services, and increasing awareness of advanced diagnostic approaches. Healthcare systems across the region are investing in modern hospitals, transplant capabilities, and specialized cardiac centers, creating greater opportunities for endomyocardial biopsy adoption. Rising demand for effective monitoring of complex cardiovascular conditions and expanding clinical expertise are further supporting market development. Improvements in healthcare accessibility and the gradual adoption of sophisticated diagnostic technologies are expected to strengthen the role of invasive cardiac tissue assessment across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Precision Diagnostic PracticeGermany prioritizes endomyocardial biopsy procedures within specialized cardiology programs focused on accurate diagnosis of myocardial disorders. Clinical centers emphasize standardized procedural techniques and multidisciplinary interpretation to support informed therapeutic decisions.
France 🇫🇷
Multidisciplinary Cardiology IntegrationFrance incorporates endomyocardial biopsy within comprehensive cardiac care pathways for transplant follow-up and difficult-to-diagnose myocardial disorders. Clinical teams prioritize coordinated pathology, imaging, and cardiology expertise to optimize diagnostic accuracy and patient management.
Italy 🇮🇹
Interventional Cardiology ExpertiseItaly's endomyocardial biopsy market benefits from experienced interventional cardiology centers performing targeted diagnostic procedures. Hospitals are emphasizing procedural quality, specialist collaboration, and evidence-based evaluation of myocardial diseases requiring tissue-based diagnosis.
Japan 🇯🇵
Transplant Monitoring SupportJapan's endomyocardial biopsy market is closely associated with post-transplant surveillance and evaluation of inflammatory heart conditions. Hospitals are strengthening procedural accuracy and pathology integration to support timely clinical intervention and long-term patient management.
South Korea 🇰🇷
Specialized Cardiac CareSouth Korea continues expanding advanced cardiovascular services that incorporate endomyocardial biopsy for selected diagnostic indications. Healthcare providers are enhancing procedural capabilities alongside imaging technologies to improve assessment of complex myocardial diseases.
United States 🇺🇸
Advanced Cardiac DiagnosticsThe U.S. endomyocardial biopsy market is supported by specialized cardiac centers managing transplant monitoring and complex cardiomyopathies. Healthcare providers continue integrating biopsy procedures with advanced imaging and pathology services to improve diagnostic confidence and treatment planning.
Endomyocardial Biopsy Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Forceps (Largest Segment) vs Accessories (Fastest-Growing Segment)
Forceps represented the largest share of the endomyocardial biopsy market at 69.02% in 2026, reflecting their essential role in obtaining myocardial tissue samples during biopsy procedures. These instruments enable clinicians to collect targeted tissue specimens for pathological and diagnostic evaluation, making them fundamental to endomyocardial biopsy workflows. Established clinical use, procedural familiarity, and the need for reliable tissue acquisition continue to sustain demand for biopsy forceps.
Accessories are expected to grow at the fastest pace as endomyocardial biopsy procedures increasingly require supporting components that facilitate procedural efficiency, safety, and compatibility with specialized equipment. Accessories can assist with instrument handling, access, guidance, and procedural preparation, contributing to smoother clinical workflows. As healthcare providers adopt increasingly sophisticated biopsy techniques and seek to improve procedural outcomes, demand for complementary equipment is expanding.
End Use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)
Hospitals led the endomyocardial biopsy market, accounting for a 54.08% share in 2026, owing to their capacity to manage specialized cardiac procedures and provide comprehensive diagnostic and post-procedural care. Endomyocardial biopsy often requires specialized expertise, advanced cardiac infrastructure, and coordinated clinical support, all of which are widely available in hospital settings. The concentration of cardiology services and complex patient management capabilities therefore reinforces the hospital segment's leading position.
Ambulatory surgical centers are anticipated to achieve the fastest growth as healthcare systems increasingly seek efficient procedural settings that can provide specialized interventions with shorter facility stays where clinically appropriate. Advances in minimally invasive cardiac procedures and improvements in procedural technologies are making selected interventions more suitable for outpatient-oriented environments. The broader movement toward cost-conscious care delivery and greater procedural efficiency is creating additional opportunities for endomyocardial biopsy services in ambulatory settings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Forceps, Accessories | Forceps | Accessories |
| End Use | Hospitals, Ambulatory Surgical Centers, Others | Hospitals | Ambulatory Surgical Centers |
| Tip | Maxi-curved, Straight, Precurved, Others | Straight | Precurved |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Key companies in the endomyocardial biopsy market:
1. Terumo Corporation (Japan)
2. Cordis Corporation (United States)
3. Argon Medical Devices Inc. (United States)
4. Mermaid Medical A/S (Denmark)
5. Scholten Surgical Instruments Inc. (United States)
6. Changzhou Lookmed Medical Instrument Co. Ltd. (China)
7. Fehling Instruments GmbH & Co. KG (Germany)
8. Biotronik SE & Co. KG (Germany)
9. Boston Scientific Corporation (United States)
10. Medtronic plc (Ireland)
The endomyocardial biopsy market is advancing with minimally invasive diagnostic technologies. Improvements in procedural accuracy are enhancing cardiovascular disease detection. The endomyocardial biopsy market continues to evolve with safer and more precise biopsy solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Terumo Corporation (Japan) | |||||||
| Cordis Corporation (United States) | |||||||
| Argon Medical Devices Inc. (United States) | |||||||
| Mermaid Medical A/S (Denmark) | |||||||
| Scholten Surgical Instruments Inc. (United States) | |||||||
| Changzhou Lookmed Medical Instrument Co. Ltd. (China) | |||||||
| Fehling Instruments GmbH & Co. KG (Germany) | |||||||
| Biotronik SE & Co. KG (Germany) | |||||||
| Boston Scientific Corporation (United States) | |||||||
| Medtronic plc (Ireland). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Teleflex Corporation | Feb-20 | Teleflex Corporation completed the acquisition of IWG High Performance Conductors, Inc., a manufacturer of minimally invasive medical products and high-performance conductors. The transaction strengthens Teleflex’s product portfolio in minimally invasive and interventional technologies, indirectly supporting cardiovascular and endomyocardial biopsy-related procedural ecosystems through broader device integration capabilities. |
| Argon Medical Devices, Inc. | Jul-19 | Argon Medical Devices entered into a definitive global licensing agreement with Hatch Medical, L.L.C. granting exclusive rights to market and distribute the Scorpion TIPS Access Systems. The agreement expands Argon’s interventional product access and commercial footprint in minimally invasive access technologies relevant to cardiovascular and related interventional procedures. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Endomyocardial Biopsy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Clinical Indication | Heart Transplant Rejection Monitoring, Cardiomyopathies, Myocarditis, Other Cardiac Conditions |
| Biopsy Approach | Right Ventricular Approach, Left Ventricular Approach, Combined/Biventricular Approach |
| Healthcare Facility Ownership | Public/Government Facilities, Private Facilities, Nonprofit/Academic Facilities |
Endomyocardial Biopsy Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Transplant Monitoring Adoption and Clinical Practice Evolution |
|
| Cardiovascular Diagnostic Workflow Assessment |
|
| Emerging Biomarker Integration Opportunities |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market size of endomyocardial biopsy?
How will the endomyocardial biopsy industry grow in terms of size and CAGR by 2036?
How is the shift toward ambulatory surgical centers reshaping procedural delivery in the endomyocardial biopsy market?
Why is demand for biopsy accessories increasing alongside established forceps utilization in cardiac diagnostic workflows?
Why are forceps the leading product in the endomyocardial biopsy market?
Why are ambulatory surgical centers the fastest-growing end-use segment in the endomyocardial biopsy market?
Why does North America lead the endomyocardial biopsy market?
What is supporting market expansion in Asia Pacific?
Which organizations are considered leaders in the endomyocardial biopsy landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook